FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896625245> ?p ?o ?g. }

• W2896625245 abstract "In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a greater number of patients with different types of malignancies.We enrolled 30 patients who were treated concurrently with anti-CCT and anti-MTB regimens between January 2006 and February 2016. Cancer and MTB treatments were administered according to the approved guidelines.Patient demographics included: men/woman: 24/6; median age: 66.5 years; Eastern Cooperative Oncology Group performance status 0-1/2/3-4: 24/4/2; Stage IIB-IIIC/IV/recurrence: 6/22/2; lung cancer (LC)/CRC/other: 15/10/5; and MTB diagnosis (before or during anti-CCT): 20/10 (LC: 8/7; CRC: 8/2; other: 4/1). For anti-CCT, 23 patients received two cytotoxic agents with or without targeted agents and 7 patients received a single cytotoxic or targeted agent. The overall response rate was 36.7%. Regarding anti-MTB chemotherapy, 22 patients received a daily drug combination containing isoniazid, rifampicin, and ethambutol, plus pyrazinamide in 15 of the 22 patients, followed by daily isoniazid and rifampicin; the remaining 8 patients received other combinations. Hematological adverse events of Grade ≥ 3 were observed in 19 (67.9%) of 28 patients; laboratory data were lost for the remaining 2. Grade 3 lymphopenia and higher were significantly more frequent in LC compared to other malignancies (P < 0.005). Non-hematological adverse events of Grade ≥ 3 were observed in 5 (16.7%) of 30 patients. One CRC patient experienced Grade 3 hemoptysis and another 2 experienced Grade 3 anaphylaxis. One patient with cholangiocellular carcinoma and gastric cancer experienced Grade 3 pseudomembranous colitis as a result of a Clostridium difficile infection. One patient (3.3%) died of pemetrexed-induced pneumonitis. The success of the anti-MTB chemotherapy was 70.0%. There were no MTB-related treatment failures. The median overall survival (months, 95.0% confidence interval) was 10.5 (8.7-36.7), 8.7 (4.7-10.0), 36.7 (minimum 2.2), and 14.4 (minimum 9.6) for all patients combined, LC, CRC, and Other malignancies, respectively. LC patients experienced delayed MTB diagnosis and shorter overall survival.Concurrent chemotherapy is effective and safe for treating cancer patients with active MTB." @default.
• W2896625245 created "2018-10-26" @default.
• W2896625245 creator A5001457372 @default.
• W2896625245 creator A5014868872 @default.
• W2896625245 creator A5017921849 @default.
• W2896625245 creator A5027517395 @default.
• W2896625245 creator A5035744584 @default.
• W2896625245 creator A5038573183 @default.
• W2896625245 creator A5041146732 @default.
• W2896625245 creator A5050014937 @default.
• W2896625245 creator A5052287605 @default.
• W2896625245 creator A5056165940 @default.
• W2896625245 creator A5057947442 @default.
• W2896625245 creator A5064593033 @default.
• W2896625245 creator A5074281551 @default.
• W2896625245 creator A5078090282 @default.
• W2896625245 creator A5089571002 @default.
• W2896625245 creator A5091673730 @default.
• W2896625245 date "2018-10-12" @default.
• W2896625245 modified "2023-10-18" @default.
• W2896625245 title "Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study" @default.
• W2896625245 cites W1577181361 @default.
• W2896625245 cites W1757492577 @default.
• W2896625245 cites W1968626722 @default.
• W2896625245 cites W200791020 @default.
• W2896625245 cites W2019041562 @default.
• W2896625245 cites W2044941487 @default.
• W2896625245 cites W2069390464 @default.
• W2896625245 cites W2076136110 @default.
• W2896625245 cites W2095201384 @default.
• W2896625245 cites W2098354753 @default.
• W2896625245 cites W2105275554 @default.
• W2896625245 cites W2133185708 @default.
• W2896625245 cites W2139248078 @default.
• W2896625245 cites W2139352203 @default.
• W2896625245 cites W2147114335 @default.
• W2896625245 cites W2161433272 @default.
• W2896625245 cites W2328006149 @default.
• W2896625245 cites W2410155863 @default.
• W2896625245 cites W2418210342 @default.
• W2896625245 cites W2538999826 @default.
• W2896625245 cites W3083236858 @default.
• W2896625245 cites W4233003559 @default.
• W2896625245 cites W4293241248 @default.
• W2896625245 doi "https://doi.org/10.1186/s12885-018-4889-1" @default.
• W2896625245 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6186130" @default.
• W2896625245 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30314434" @default.
• W2896625245 hasPublicationYear "2018" @default.
• W2896625245 type Work @default.
• W2896625245 sameAs 2896625245 @default.
• W2896625245 citedByCount "16" @default.
• W2896625245 countsByYear W28966252452018 @default.
• W2896625245 countsByYear W28966252452020 @default.
• W2896625245 countsByYear W28966252452021 @default.
• W2896625245 countsByYear W28966252452022 @default.
• W2896625245 countsByYear W28966252452023 @default.
• W2896625245 crossrefType "journal-article" @default.
• W2896625245 hasAuthorship W2896625245A5001457372 @default.
• W2896625245 hasAuthorship W2896625245A5014868872 @default.
• W2896625245 hasAuthorship W2896625245A5017921849 @default.
• W2896625245 hasAuthorship W2896625245A5027517395 @default.
• W2896625245 hasAuthorship W2896625245A5035744584 @default.
• W2896625245 hasAuthorship W2896625245A5038573183 @default.
• W2896625245 hasAuthorship W2896625245A5041146732 @default.
• W2896625245 hasAuthorship W2896625245A5050014937 @default.
• W2896625245 hasAuthorship W2896625245A5052287605 @default.
• W2896625245 hasAuthorship W2896625245A5056165940 @default.
• W2896625245 hasAuthorship W2896625245A5057947442 @default.
• W2896625245 hasAuthorship W2896625245A5064593033 @default.
• W2896625245 hasAuthorship W2896625245A5074281551 @default.
• W2896625245 hasAuthorship W2896625245A5078090282 @default.
• W2896625245 hasAuthorship W2896625245A5089571002 @default.
• W2896625245 hasAuthorship W2896625245A5091673730 @default.
• W2896625245 hasBestOaLocation W28966252451 @default.
• W2896625245 hasConcept C121608353 @default.
• W2896625245 hasConcept C126322002 @default.
• W2896625245 hasConcept C141071460 @default.
• W2896625245 hasConcept C142724271 @default.
• W2896625245 hasConcept C143998085 @default.
• W2896625245 hasConcept C167135981 @default.
• W2896625245 hasConcept C197934379 @default.
• W2896625245 hasConcept C2776228421 @default.
• W2896625245 hasConcept C2776256026 @default.
• W2896625245 hasConcept C2776694085 @default.
• W2896625245 hasConcept C2776967927 @default.
• W2896625245 hasConcept C2777975735 @default.
• W2896625245 hasConcept C2778607973 @default.
• W2896625245 hasConcept C2780140570 @default.
• W2896625245 hasConcept C2780459521 @default.
• W2896625245 hasConcept C2781069245 @default.
• W2896625245 hasConcept C71924100 @default.
• W2896625245 hasConcept C90924648 @default.
• W2896625245 hasConceptScore W2896625245C121608353 @default.
• W2896625245 hasConceptScore W2896625245C126322002 @default.
• W2896625245 hasConceptScore W2896625245C141071460 @default.
• W2896625245 hasConceptScore W2896625245C142724271 @default.
• W2896625245 hasConceptScore W2896625245C143998085 @default.
• W2896625245 hasConceptScore W2896625245C167135981 @default.
• W2896625245 hasConceptScore W2896625245C197934379 @default.
• W2896625245 hasConceptScore W2896625245C2776228421 @default.

• next